{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\" and document_type = \"Notice\" sorted by posted_date descending", "rows": [["FDA-2025-N-0421-0002", "FDA", "FDA-2025-N-0421", "Oscar Bobo: Final Debarment Order", "Notice", "Statutory Debarment", "2026-05-15T04:00:00Z", 2026, 5, "2026-05-15T04:00:00Z", null, "2026-05-15T17:48:54Z", "2026-09767", 1, 0, "09000064b92da9bd"], ["FDA-2026-N-4126-0001", "FDA", "FDA-2026-N-4126", "Azodicarbonamide (ADA); Request for Information", "Notice", "Requests for Information (RFI)", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", "2026-07-14T03:59:59Z", "2026-05-13T17:13:38Z", "2026-09508", 1, 0, "09000064b92d17fd"], ["FDA-2026-N-3098-0001", "FDA", "FDA-2026-N-3098", "Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting", "Notice", "60 Day Proposed Information Collection", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", "2026-07-14T03:59:59Z", "2026-05-13T16:56:28Z", "2026-09543", 1, 0, "09000064b92d4966"], ["FDA-2026-N-2526-0001", "FDA", "FDA-2026-N-2526", "Butylated Hydroxytoluene (BHT); Request for Information", "Notice", "Requests for Information (RFI)", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", "2026-07-14T03:59:59Z", "2026-05-13T17:01:00Z", "2026-09507", 1, 0, "09000064b92d4931"], ["FDA-2019-N-0994-0230", "FDA", "FDA-2019-N-0994", "Modified Risk Tobacco Product Application: Renewal Applications for\nVLN\u00ae King and VLN\u00ae Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.", "Notice", "Request for Comments", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", null, "2026-05-15T09:00:24Z", "2026-09544", 1, 0, "09000064b92d47df"], ["FDA-2025-N-1600-0003", "FDA", "FDA-2025-N-1600", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3", "Notice", "30 Day Proposed Information Collection", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", "2026-06-13T03:59:59Z", "2026-05-13T17:17:21Z", "2026-09448", 1, 0, "09000064b92d4828"], ["FDA-2026-N-0005-0001", "FDA", "FDA-2026-N-0005", "Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information", "Notice", "Requests for Information (RFI)", "2026-05-13T04:00:00Z", 2026, 5, "2026-05-13T04:00:00Z", "2026-07-14T03:59:59Z", "2026-05-13T17:06:21Z", "2026-09533", 1, 0, "09000064b92d48f3"], ["FDA-2026-N-4492-0001", "FDA", "FDA-2026-N-4492", "Drug Repurposing for Unmet Medical Needs; Request for Information", "Notice", "Requests for Information (RFI)", "2026-05-12T04:00:00Z", 2026, 5, "2026-05-12T04:00:00Z", "2026-06-12T03:59:59Z", "2026-05-15T09:00:24Z", "2026-09366", 1, 0, "09000064b92d15f4"], ["FDA-2017-N-5925-0040", "FDA", "FDA-2017-N-5925", "21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria web page", "Notice", "Request for Comments", "2026-05-12T04:00:00Z", 2026, 5, "2026-05-12T04:00:00Z", null, "2026-05-12T22:58:36Z", "2026-09438", 1, 0, "09000064b92d17af"], ["FDA-2026-D-5083-0001", "FDA", "FDA-2026-D-5083", "Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-05-12T04:00:00Z", 2026, 5, "2026-05-12T04:00:00Z", null, "2026-05-12T17:17:05Z", "2026-09368", 0, 0, "09000064b92d1762"], ["FDA-2025-N-2220-0002", "FDA", "FDA-2025-N-2220", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products", "Notice", "30 Day Proposed Information Collection", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", "2026-06-11T03:59:59Z", "2026-05-11T21:25:31Z", "2026-09244", 1, 0, "09000064b92cfa18"], ["FDA-2011-N-0655-0042", "FDA", "FDA-2011-N-0655", "Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for\nNotification of Stakeholder Intent To Participate", "Notice", "Notice of Intent", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T21:26:21Z", "2026-09284", 0, 0, "09000064b92cf91b"], ["FDA-2026-N-4573-0001", "FDA", "FDA-2026-N-4573", "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm)", "Notice", "Announcement", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T17:34:15Z", "2026-09242", 0, 0, "09000064b92cf987"], ["FDA-2013-D-1319-0015", "FDA", "FDA-2013-D-1319", "Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T17:27:37Z", "2026-09269", 0, 0, "09000064b92cf98a"], ["FDA-2018-D-4693-0022", "FDA", "FDA-2018-D-4693", "Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T17:36:17Z", "2026-09268", 0, 0, "09000064b92cf982"], ["FDA-2011-N-0656-1315", "FDA", "FDA-2011-N-0656", "Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder\nIntent To Participate", "Notice", "General Notice", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T17:56:32Z", "2026-09283", 0, 0, "09000064b92cacd0"], ["FDA-2022-D-1261-0003", "FDA", "FDA-2022-D-1261", "Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-05-11T04:00:00Z", 2026, 5, "2026-05-11T04:00:00Z", null, "2026-05-11T17:42:11Z", "2026-09267", 0, 0, "09000064b92cf922"], ["FDA-2026-P-0749-0004", "FDA", "FDA-2026-P-0749", "Determination That Leucovorin Calcium, Oral Solution, Equivalent to 60 Milligrams Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-05-08T04:00:00Z", 2026, 5, null, null, "2026-05-08T17:04:13Z", "2026-09199", 0, 0, "09000064b92c97d0"], ["FDA-2025-P-7054-0006", "FDA", "FDA-2025-P-7054", "Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-05-07T04:00:00Z", 2026, 5, "2026-05-07T04:00:00Z", null, "2026-05-07T17:15:35Z", "2026-09011", 0, 0, "09000064b92c66bf"], ["FDA-2023-D-2370-0007", "FDA", "FDA-2023-D-2370", "Patient-Matched Guides for Orthopedic Implants; Guidance for Industry and Food and Drug Administration Staff; Availability", "Notice", "Notice of Availability", "2026-05-07T04:00:00Z", 2026, 5, "2026-05-07T04:00:00Z", null, "2026-05-07T17:05:32Z", "2026-09023", 0, 0, "09000064b92c78fc"], ["FDA-2026-N-4291-0001", "FDA", "FDA-2026-N-4291", "Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications", "Notice", "Withdrawal", "2026-05-07T04:00:00Z", 2026, 5, "2026-05-07T04:00:00Z", null, "2026-05-07T16:54:25Z", "2026-09012", 0, 0, "09000064b92c85aa"], ["FDA-2026-N-0008-0004", "FDA", "FDA-2026-N-0008", "Advisory Committee; Blood Products Advisory Committee; Renewal", "Notice", "Notice of Renewal", "2026-05-07T04:00:00Z", 2026, 5, "2026-05-07T04:00:00Z", null, "2026-05-07T17:02:15Z", "2026-09108", 0, 0, "09000064b92c85a3"], ["FDA-2026-N-4588-0001", "FDA", "FDA-2026-N-4588", "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha)", "Notice", "Announcement", "2026-05-06T04:00:00Z", 2026, 5, "2026-05-06T04:00:00Z", null, "2026-05-06T17:40:41Z", "2026-08913", 0, 0, "09000064b92c5bca"], ["FDA-2026-P-1306-0004", "FDA", "FDA-2026-P-1306", "Determination That DEXAMETHASONE (Dexamethasone) Elixir, 0.5 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-05-06T04:00:00Z", 2026, 5, "2026-05-06T04:00:00Z", null, "2026-05-06T17:34:01Z", "2026-08939", 0, 0, "09000064b92c65a4"], ["FDA-2026-N-3070-0001", "FDA", "FDA-2026-N-3070", "Agency Information Collection Activities; Proposed Collection; Comment Request; National Youth Tobacco Survey", "Notice", "60 Day Proposed Information Collection", "2026-05-04T04:00:00Z", 2026, 5, "2026-05-04T04:00:00Z", "2026-07-07T03:59:59Z", "2026-05-04T19:19:25Z", "2026-08604", 1, 0, "09000064b92c115c"], ["FDA-2018-N-3240-0377", "FDA", "FDA-2018-N-3240", "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act", "Notice", "Request for Comments", "2026-05-01T04:00:00Z", 2026, 5, "2026-05-01T04:00:00Z", "2026-07-01T03:59:59Z", "2026-05-16T09:00:17Z", "2026-08552", 1, 0, "09000064b92bb724"], ["FDA-2026-N-3499-0001", "FDA", "FDA-2026-N-3499", "Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments", "Notice", "Request for Comments", "2026-05-01T04:00:00Z", 2026, 5, "2026-05-01T04:00:00Z", "2026-07-01T03:59:59Z", "2026-05-02T09:00:17Z", "2026-08521", 1, 0, "09000064b92bb7fb"], ["FDA-2026-N-3947-0001", "FDA", "FDA-2026-N-3947", "Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments", "Notice", "Request for Comments", "2026-05-01T04:00:00Z", 2026, 5, "2026-05-01T04:00:00Z", "2026-07-01T03:59:59Z", "2026-05-09T09:00:22Z", "2026-08524", 1, 0, "09000064b92bb6d7"], ["FDA-2026-N-4268-0001", "FDA", "FDA-2026-N-4268", "Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments", "Notice", "Request for Comments", "2026-05-01T04:00:00Z", 2026, 5, "2026-05-01T04:00:00Z", "2026-07-01T03:59:59Z", "2026-05-09T09:00:22Z", "2026-08499", 1, 0, "09000064b92bb7b3"], ["FDA-2026-P-0655-0003", "FDA", "FDA-2026-P-0655", "Determination FENOGLIDE (Fenofibrate) Tablets, 40 Milligrams and 120 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-04-30T04:00:00Z", 2026, 4, null, null, "2026-04-30T17:56:39Z", "2026-08390", 0, 0, "09000064b92b7f6c"], ["FDA-2026-N-0499-0002", "FDA", "FDA-2026-N-0499", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice", "Notice", "30 Day Proposed Information Collection", "2026-04-30T04:00:00Z", 2026, 4, "2026-04-30T04:00:00Z", "2026-06-02T03:59:59Z", "2026-04-30T17:46:42Z", "2026-08417", 1, 0, "09000064b92b80f2"], ["FDA-2026-N-0008-0003", "FDA", "FDA-2026-N-0008", "Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal", "Notice", "Notice of Renewal", "2026-04-30T04:00:00Z", 2026, 4, null, null, "2026-04-30T18:03:08Z", "2026-08378", 0, 0, "09000064b92b7f20"], ["FDA-2025-P-3849-0004", "FDA", "FDA-2025-P-3849", "Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-04-30T04:00:00Z", 2026, 4, null, null, "2026-04-30T18:12:42Z", "2026-08435", 0, 0, "09000064b92b5df8"], ["FDA-2026-N-3532-0001", "FDA", "FDA-2026-N-3532", "Agency Information Collection Activities; Proposed Collection; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies", "Notice", "60 Day Proposed Information Collection", "2026-04-30T04:00:00Z", 2026, 4, "2026-04-30T04:00:00Z", "2026-06-30T03:59:59Z", "2026-05-02T09:00:17Z", "2026-08371", 1, 0, "09000064b92b7fb3"], ["FDA-2026-N-1321-0001", "FDA", "FDA-2026-N-1321", "ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing", "Notice", "Withdrawal", "2026-04-30T04:00:00Z", 2026, 4, "2026-04-30T04:00:00Z", "2026-06-30T03:59:59Z", "2026-05-16T09:00:16Z", "2026-08455", 1, 0, "09000064b92b7e81"], ["FDA-2026-N-4390-0001", "FDA", "FDA-2026-N-4390", "AI-Enabled Optimization of Early- Phase Clinical Trials Pilot Program; Request for Information", "Notice", "Requests for Information (RFI)", "2026-04-29T04:00:00Z", 2026, 4, "2026-04-29T04:00:00Z", "2026-05-30T03:59:59Z", "2026-05-16T12:32:04Z", "2026-08281", 1, 0, "09000064b92b54c8"], ["FDA-2026-N-1832-0014", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1303 - Bifidobacterium animalis subsp. lactis CGMCC5470", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:48Z", null, 0, 0, "09000064b92a8cd6"], ["FDA-2025-N-1928-0067", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1279 \u2013 Saccharomyces cerevisiae CCTCC M2025194 \u2013 amendments", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:24:49Z", null, 0, 0, "09000064b92a80fa"], ["FDA-2026-N-1832-0008", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 3 of 3", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:28:45Z", null, 0, 0, "09000064b92a8ccc"], ["FDA-2025-N-1928-0066", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1278 \u2013 Lactiplantibacillus plantarum CGMCC 6312 \u2013 amendments", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:24:47Z", null, 0, 0, "09000064b92a80f9"], ["FDA-2025-N-1928-0064", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1256 \u2013 Lemna leaf protein \u2013 amendments", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:18:46Z", null, 0, 0, "09000064b92a80f7"], ["FDA-2026-N-1832-0007", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 2 of 3", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:28:26Z", null, 0, 0, "09000064b92a8ccb"], ["FDA-2025-N-1928-0065", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1276 \u2013 Cellulase enzyme preparation produced by Trichoderma reesei expressing a gene encoding a cellulase from Aspergillus niger \u2013 amendments", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:24:37Z", null, 0, 0, "09000064b92a80f8"], ["FDA-2026-N-1832-0015", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1304 - Preparation containing at least three bacteriophages (phage) specific to Listeria spp.", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:52Z", null, 0, 0, "09000064b92a8cd7"], ["FDA-2026-N-1832-0003", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1293 - Brazzein preparation produced by Komagataella phaffii \u201cRA-b\u201d expressing a gene encoding for brazzein from Pentadiplandra brazzeana - Part 2 of 2", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:27:02Z", null, 0, 0, "09000064b92a8cc6"], ["FDA-2026-N-1832-0005", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1295 - Brazzein preparation produced by Komagataella phaffii GS115 expressing a gene encoding for brazzein from Pentadiplandra brazzeana", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:27:45Z", null, 0, 0, "09000064b92a8cc9"], ["FDA-2025-N-1928-0069", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1296 - Erythritol produced through fermentation of glucose by Yarrowia lipolytica", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:25:01Z", null, 0, 0, "09000064b92a80fc"], ["FDA-2025-N-1928-0068", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1292 - Citrus-derived compounded sweetener made with neohesperidin dihydrochalcone and gamma cyclodextrin", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:24:59Z", null, 0, 0, "09000064b92a80fb"], ["FDA-2026-N-1832-0010", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1299 - 3'-Sialyllactose (3'-SL) Sodium Salt", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:24Z", null, 0, 0, "09000064b92a8ccf"], ["FDA-2026-N-1832-0006", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 1 of 3", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:27:58Z", null, 0, 0, "09000064b92a8cca"], ["FDA-2026-N-1832-0012", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1301 - Algal oil (\u226545% docosahexaenoic acid from Schizochytrium sp. \u201cJDW-108\u201d)", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:36Z", null, 0, 0, "09000064b92a8cd4"], ["FDA-2026-N-1832-0002", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1293 - Brazzein preparation produced by Komagataella phaffii \u201cRA-b\u201d expressing a gene encoding for brazzein from Pentadiplandra brazzeana - Part 1 of 2", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:26:49Z", null, 0, 0, "09000064b92a8cc5"], ["FDA-2026-N-1832-0004", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1294 - Rebaudioside M produced by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:27:15Z", null, 0, 0, "09000064b92a8cc7"], ["FDA-2026-N-1832-0009", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1298 - 2'-fucosyllactose", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:07Z", null, 0, 0, "09000064b92a8ccd"], ["FDA-2026-N-1832-0013", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1302 - Fermented grape pomace", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:44Z", null, 0, 0, "09000064b92a8cd5"], ["FDA-2026-N-1832-0001", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1291 - Wattle Seeds (Acacia longifolia)", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:26:31Z", null, 0, 0, "09000064b92a8cc4"], ["FDA-2026-N-1832-0011", "FDA", "FDA-2026-N-1832", "GRAS Notice (GRN) 1300 \u2013 Zeaxanthin", "Notice", "General Notice", "2026-04-28T04:00:00Z", 2026, 4, "2026-04-28T04:00:00Z", null, "2026-04-28T16:29:32Z", null, 0, 0, "09000064b92a8cd1"], ["FDA-2022-N-0621-0003", "FDA", "FDA-2022-N-0621", "Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal", "Notice", "Renewals", "2026-04-27T04:00:00Z", 2026, 4, null, null, "2026-04-27T17:18:57Z", "2026-08125", 0, 0, "09000064b92ad1da"], ["FDA-2026-N-3962-0001", "FDA", "FDA-2026-N-3962", "Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments\u2014\nUnited States (U.S.) 2026\u20132027 Formula for COVID\u201319 Vaccine Composition", "Notice", "Request for Comments", "2026-04-27T04:00:00Z", 2026, 4, "2026-04-27T04:00:00Z", "2026-05-28T03:59:59Z", "2026-05-16T09:00:16Z", "2026-08122", 1, 0, "09000064b92ad21d"], ["FDA-2026-N-3445-0001", "FDA", "FDA-2026-N-3445", "Egis Pharmaceuticals Limited, et al.; Withdrawal of Approval of Three Abbreviated New Drug Applications", "Notice", "Withdrawal", "2026-04-24T04:00:00Z", 2026, 4, "2026-04-24T04:00:00Z", null, "2026-04-24T18:50:43Z", "2026-08020", 0, 0, "09000064b92a8517"], ["FDA-2026-N-3334-0001", "FDA", "FDA-2026-N-3334", "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and\nCommitments; Availability", "Notice", "Announcement", "2026-04-24T04:00:00Z", 2026, 4, "2026-04-24T04:00:00Z", null, "2026-04-24T18:41:49Z", "2026-08084", 0, 0, "09000064b92a8592"], ["FDA-2026-N-2642-0001", "FDA", "FDA-2026-N-2642", "Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments", "Notice", "Request for Comments", "2026-04-23T04:00:00Z", 2026, 4, "2026-04-23T04:00:00Z", "2026-05-27T03:59:59Z", "2026-05-16T09:00:16Z", "2026-07910", 1, 0, "09000064b92a4e3b"], ["FDA-2025-N-7055-0002", "FDA", "FDA-2025-N-7055", "Kimberly Schaff Kiehl: Final Debarment Order", "Notice", "Statutory Debarment", "2026-04-23T04:00:00Z", 2026, 4, "2026-04-23T04:00:00Z", null, "2026-04-24T19:52:58Z", "2026-07864", 1, 0, "09000064b92a4e3c"], ["FDA-2026-N-2366-0010", "FDA", "FDA-2026-N-2366", "Commissioner\u2019s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments; Amendment", "Notice", "Request for Comments", "2026-04-23T04:00:00Z", 2026, 4, "2026-04-23T04:00:00Z", null, "2026-04-23T17:36:23Z", "2026-07916", 0, 0, "09000064b92a4d6f"], ["FDA-2025-D-6130-0001", "FDA", "FDA-2025-D-6130", "Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-04-20T04:00:00Z", 2026, 4, "2026-04-20T04:00:00Z", null, "2026-04-20T17:35:59Z", "2026-07629", 0, 0, "09000064b9293df3"], ["FDA-2025-D-7121-0001", "FDA", "FDA-2025-D-7121", "Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators; Draft Guidance for Industry and Food and Drug\nAdministration Staff; Availability", "Notice", "Notice of Availability", "2026-04-20T04:00:00Z", 2026, 4, "2026-04-20T04:00:00Z", null, "2026-04-20T17:40:49Z", "2026-07613", 0, 0, "09000064b929309a"], ["FDA-2025-N-6743-2002", "FDA", "FDA-2025-N-6743", "Potential New Indication for Testosterone Replacement Therapy", "Notice", "Announcement", "2026-04-20T04:00:00Z", 2026, 4, "2026-04-20T04:00:00Z", null, "2026-04-20T17:25:47Z", "2026-07615", 0, 0, "09000064b9293dfa"], ["FDA-2026-N-2917-0001", "FDA", "FDA-2026-N-2917", "Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed", "Notice", "60 Day Proposed Information Collection", "2026-04-17T04:00:00Z", 2026, 4, "2026-04-17T04:00:00Z", "2026-06-17T03:59:59Z", "2026-04-17T16:47:09Z", "2026-07501", 1, 0, "09000064b9289353"], ["FDA-2011-N-0655-0041", "FDA", "FDA-2011-N-0655", "Animal Generic Drug User Fee Act; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-17T04:00:00Z", 2026, 4, "2026-04-17T04:00:00Z", "2027-12-02T04:59:59Z", "2026-04-17T17:16:13Z", "2026-07497", 1, 0, "09000064b928930a"], ["FDA-2011-N-0656-1314", "FDA", "FDA-2011-N-0656", "Animal Drug User Fee Act; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-17T04:00:00Z", 2026, 4, "2026-04-17T04:00:00Z", "2027-12-02T04:59:59Z", "2026-04-17T17:15:38Z", "2026-07498", 1, 0, "09000064b928948d"], ["FDA-2026-N-3099-0001", "FDA", "FDA-2026-N-3099", "Agency Information Collection Activities; Proposed Collection; Comment Request; Radioactive Drug Research Committees", "Notice", "60 Day Proposed Information Collection", "2026-04-17T04:00:00Z", 2026, 4, "2026-04-17T04:00:00Z", "2026-06-17T03:59:59Z", "2026-04-17T16:55:18Z", "2026-07507", 1, 0, "09000064b9289303"], ["FDA-2026-N-3799-0001", "FDA", "FDA-2026-N-3799", "Authorization of Emergency Use for Four Animal Drugs for the Treatment of New World Screwworm; Availability", "Notice", "Announcement", "2026-04-17T04:00:00Z", 2026, 4, "2026-04-17T04:00:00Z", null, "2026-04-17T16:43:08Z", "2026-07509", 0, 0, "09000064b928935b"], ["FDA-2025-E-0501-0006", "FDA", "FDA-2025-E-0501", "Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT", "Notice", "Determinations", "2026-04-16T04:00:00Z", 2026, 4, "2026-04-16T04:00:00Z", "2026-06-16T03:59:59Z", "2026-04-16T17:49:56Z", "2026-07422", 1, 0, "09000064b928671f"], ["FDA-2025-E-0502-0006", "FDA", "FDA-2025-E-0502", "Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT", "Notice", "Determinations", "2026-04-16T04:00:00Z", 2026, 4, "2026-04-16T04:00:00Z", "2026-06-16T03:59:59Z", "2026-04-16T17:53:26Z", "2026-07422", 1, 0, "09000064b9286364"], ["FDA-2026-N-3400-0001", "FDA", "FDA-2026-N-3400", "Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs", "Notice", "60 Day Proposed Information Collection", "2026-04-16T04:00:00Z", 2026, 4, "2026-04-16T04:00:00Z", "2026-06-16T03:59:59Z", "2026-04-18T09:00:22Z", "2026-07423", 1, 0, "09000064b9286561"], ["FDA-2025-N-6895-0001", "FDA", "FDA-2025-N-6895", "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments\u2014Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List", "Notice", "Request for Comments", "2026-04-16T04:00:00Z", 2026, 4, "2026-04-16T04:00:00Z", "2026-07-23T03:59:59Z", "2026-05-15T09:00:20Z", "2026-07361", 1, 0, "09000064b92865ab"], ["FDA-2021-D-0613-0002", "FDA", "FDA-2021-D-0613", "International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Stability Testing for Medicated\nPremixes (Revision 1); Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T18:45:04Z", "2026-07419", 0, 0, "09000064b9286528"], ["FDA-2026-N-3466-0001", "FDA", "FDA-2026-N-3466", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)", "Notice", "Notice of Approval", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T18:40:24Z", "2026-07370", 0, 0, "09000064b9286529"], ["FDA-2025-P-4154-0004", "FDA", "FDA-2025-P-4154", "Determination That CHEWTADZY (Tadalafil) Chewable Tablets, 5 Milligrams, 10 Milligrams, 20 Milligrams, Were Not Withdrawn From\nSale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T17:43:18Z", "2026-07443", 0, 0, "09000064b92867ad"], ["FDA-2026-N-3500-0001", "FDA", "FDA-2026-N-3500", "Notice of Approval of Product Under Priority Review Voucher; Material Threat Medical Countermeasure Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)", "Notice", "Notice of Approval", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T17:45:21Z", "2026-07369", 0, 0, "09000064b9286771"], ["FDA-2026-N-3240-0001", "FDA", "FDA-2026-N-3240", "Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs", "Notice", "60 Day Proposed Information Collection", "2026-04-16T04:00:00Z", 2026, 4, "2026-04-16T04:00:00Z", "2026-06-16T03:59:59Z", "2026-04-16T18:04:30Z", "2026-07421", 1, 0, "09000064b92866e7"], ["FDA-2025-P-4151-0004", "FDA", "FDA-2025-P-4151", "Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 Milligrams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T18:24:57Z", "2026-07451", 0, 0, "09000064b928652f"], ["FDA-2026-N-3446-0001", "FDA", "FDA-2026-N-3446", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)", "Notice", "Notice of Approval", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T18:19:33Z", "2026-07368", 0, 0, "09000064b9286565"], ["FDA-2026-N-3447-0001", "FDA", "FDA-2026-N-3447", "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MNEXSPIKE (COVID\u201319 Vaccine, mRNA)", "Notice", "Notice of Approval", "2026-04-16T04:00:00Z", 2026, 4, null, null, "2026-04-16T18:06:41Z", "2026-07371", 0, 0, "09000064b92866e5"], ["FDA-2026-D-1255-0001", "FDA", "FDA-2026-D-1255", "Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2026-04-15T04:00:00Z", 2026, 4, "2026-04-15T04:00:00Z", null, "2026-04-15T17:11:56Z", "2026-07285", 0, 0, "09000064b92810b1"], ["FDA-2025-N-4731-0052", "FDA", "FDA-2025-N-4731", "Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-15T04:00:00Z", 2026, 4, "2026-04-23T04:00:00Z", "2026-05-09T03:59:59Z", "2026-05-09T09:00:20Z", "2026-07335", 0, 0, "09000064b9282192"], ["FDA-2026-N-3273-0001", "FDA", "FDA-2026-N-3273", "Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments", "Notice", "Request for Comments", "2026-04-15T04:00:00Z", 2026, 4, "2026-04-15T04:00:00Z", "2026-07-24T03:59:59Z", "2026-04-15T17:05:22Z", "2026-07248", 1, 0, "09000064b9282224"], ["FDA-2025-P-2524-0004", "FDA", "FDA-2025-P-2524", "Determination That BILTRICIDE (Praziquantel) Oral Tablet, 600 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness", "Notice", "Determinations", "2026-04-13T04:00:00Z", 2026, 4, "2026-04-13T04:00:00Z", null, "2026-04-13T21:09:10Z", "2026-07059", 0, 0, "09000064b9272b56"], ["FDA-2026-N-0707-0001", "FDA", "FDA-2026-N-0707", "GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (Leucovorin Calcium) Tablets, EQ 5 mg Base and EQ 25 mg Base", "Notice", "Withdrawal", "2026-04-10T04:00:00Z", 2026, 4, "2026-04-10T04:00:00Z", null, "2026-04-10T17:40:29Z", "2026-06911", 0, 0, "09000064b926837d"], ["FDA-2026-N-2742-0001", "FDA", "FDA-2026-N-2742", "Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification", "Notice", "60 Day Proposed Information Collection", "2026-04-10T04:00:00Z", 2026, 4, "2026-04-10T04:00:00Z", "2026-06-10T03:59:59Z", "2026-04-10T18:01:37Z", "2026-06936", 1, 0, "09000064b926825a"], ["FDA-2026-N-2743-0001", "FDA", "FDA-2026-N-2743", "Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503", "Notice", "60 Day Proposed Information Collection", "2026-04-10T04:00:00Z", 2026, 4, "2026-04-10T04:00:00Z", "2026-06-10T03:59:59Z", "2026-04-20T09:00:32Z", "2026-06935", 1, 0, "09000064b926821b"], ["FDA-2026-N-2915-0001", "FDA", "FDA-2026-N-2915", "Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices", "Notice", "60 Day Proposed Information Collection", "2026-04-10T04:00:00Z", 2026, 4, "2026-04-10T04:00:00Z", "2026-06-10T03:59:59Z", "2026-04-10T17:47:50Z", "2026-06906", 1, 0, "09000064b9268328"], ["FDA-2025-N-1928-0061", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1283 - Bacillus coagulans BC99 spore preparation - amendment", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:16:57Z", null, 0, 0, "09000064b925c73b"], ["FDA-2025-N-1928-0063", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1287 - Sucrose oligoesters - amendments", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:17:22Z", null, 0, 0, "09000064b925c73d"], ["FDA-2025-N-1928-0058", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1266 - Wheat fiber extract from wheat (Triticumaestivum) - amendments", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:16:16Z", null, 0, 0, "09000064b925c737"], ["FDA-2025-N-1928-0059", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1271 - Short Chain Fructooligosaccharides - amendments", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:16:28Z", null, 0, 0, "09000064b925c738"], ["FDA-2025-N-1928-0060", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1275 - 6'-Sialyllactose sodium salt - amendments", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:16:42Z", null, 0, 0, "09000064b925c73a"], ["FDA-2025-N-1928-0062", "FDA", "FDA-2025-N-1928", "GRAS Notice (GRN) 1284 - Recombinant bovine lactoferrin isolate produced by Komagataella phaffii \u201cPpas_337\u201d expressing the gene encoding bovine lactoferrin \u2013 amendments", "Notice", "General Notice", "2026-04-08T04:00:00Z", 2026, 4, "2026-04-08T04:00:00Z", null, "2026-04-08T18:17:10Z", null, 0, 0, "09000064b925c73c"], ["FDA-2026-N-3058-0001", "FDA", "FDA-2026-N-3058", "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln)", "Notice", "Announcement", "2026-04-07T04:00:00Z", 2026, 4, "2026-04-07T04:00:00Z", null, "2026-04-07T18:06:33Z", "2026-06722", 0, 0, "09000064b9256d79"], ["FDA-2026-N-2431-0001", "FDA", "FDA-2026-N-2431", "Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings", "Notice", "60 Day Proposed Information Collection", "2026-04-07T04:00:00Z", 2026, 4, "2026-04-07T04:00:00Z", "2026-06-09T03:59:59Z", "2026-05-12T09:00:14Z", "2026-06719", 1, 0, "09000064b9255485"]], "truncated": false, "filtered_table_rows_count": 19752, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"document_type\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "Notice"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice", "results": [{"value": "FDA", "label": "FDA", "count": 19752, "toggle_url": "https://pawtectors.org/openregs/documents.json?document_type=Notice", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice", "results": [{"value": "Notice", "label": "Notice", "count": 19752, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA", "selected": true}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&document_type=Notice", "results": [{"value": 2018, "label": 2018, "count": 1085, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2018", "selected": false}, {"value": 2016, "label": 2016, "count": 1014, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2016", "selected": false}, {"value": 2017, "label": 2017, "count": 969, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2017", "selected": false}, {"value": 2014, "label": 2014, "count": 932, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2014", "selected": false}, {"value": 2023, "label": 2023, "count": 896, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2023", "selected": false}, {"value": 2015, "label": 2015, "count": 869, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2015", "selected": false}, {"value": 2011, "label": 2011, "count": 837, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2011", "selected": false}, {"value": 2022, "label": 2022, "count": 827, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2022", "selected": false}, {"value": 2021, "label": 2021, "count": 822, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2021", "selected": false}, {"value": 2024, "label": 2024, "count": 804, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2024", "selected": false}, {"value": 2019, "label": 2019, "count": 799, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2019", "selected": false}, {"value": 2010, "label": 2010, "count": 797, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2010", "selected": false}, {"value": 2020, "label": 2020, "count": 778, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2020", "selected": false}, {"value": 2025, "label": 2025, "count": 751, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2025", "selected": false}, {"value": 2009, "label": 2009, "count": 735, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2009", "selected": false}, {"value": 2012, "label": 2012, "count": 720, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2012", "selected": false}, {"value": 2013, "label": 2013, "count": 718, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2013", "selected": false}, {"value": 2007, "label": 2007, "count": 669, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2007", "selected": false}, {"value": 2008, "label": 2008, "count": 607, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2008", "selected": false}, {"value": 2003, "label": 2003, "count": 579, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2003", "selected": false}, {"value": 2004, "label": 2004, "count": 536, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2004", "selected": false}, {"value": 2006, "label": 2006, "count": 526, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2006", "selected": false}, {"value": 2002, "label": 2002, "count": 521, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2002", "selected": false}, {"value": 2005, "label": 2005, "count": 473, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2005", "selected": false}, {"value": 2026, "label": 2026, "count": 328, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2026", "selected": false}, {"value": 1996, "label": 1996, "count": 308, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=1996", "selected": false}, {"value": 2000, "label": 2000, "count": 259, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2000", "selected": false}, {"value": 2001, "label": 2001, "count": 192, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=2001", "selected": false}, {"value": 1999, "label": 1999, "count": 127, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=1999", "selected": false}, {"value": 1998, "label": 1998, "count": 84, "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&posted_year=1998", "selected": false}], "truncated": true}}, "suggested_facets": [{"name": "posted_date", "type": "date", "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&_facet_date=last_modified"}], "next": "2026-04-07T04~3A00~3A00Z,FDA-2026-N-2431-0001", "next_url": "https://pawtectors.org/openregs/documents.json?agency_id=FDA&document_type=Notice&_next=2026-04-07T04~3A00~3A00Z%2CFDA-2026-N-2431-0001&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 2581.2987911049277, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}